借超分子“印迹模板”的自主作用解开金(山)银花纷争  

Dispute for Japanese( wild) honeysuckle flower based on supermolecular imprinting templates

作　　者：贺福元[1,2,3,4] 贺红[1,2,3,4] 邓凯文[5] 杨岩涛[1,2,4] 周逸群[1,2,4] 石继连[1,2,4] 刘文龙[1,2,4] 唐宇[2,4] 

机构地区：[1]湖南中医药大学药学院药剂教研室,湖南长沙410208 [2]中药药性与药效国家中医药管理局重点实验室,湖南长沙410208 [3]湖南中医药大学现代中药制剂制备技术与评价实验室,湖南长沙410208 [4]湖南中医药大学中医药超分子机理与数理特征化实验室,湖南长沙410208 [5]湖南中医药大学第一附属医院,湖南长沙410007

出　　处：《中国中药杂志》2016年第6期1152-1160,共9页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金项目(81270055;81573691);湖南省自然科学基金项目(2015JJ2111);国家博士点基金项目(20124323110002);湖南省教育厅"十二五"药学重点学科项目

摘　　要：自2005年版《中国药典》将金(山)银花分列后,纷争便不断上演,且愈演愈烈。尽管《中国药典》将"双花"分列,却没有给出两者在中药药性、功效主治、用法用量的差异以及具体解决办法,难以使中药行业人员信服。众所周知,在漫长的中药入药史上,一药多种,一种多药的现象俯首可拾;到底能合能分应该由临床等效情况确定。透过2015年版《中国药典》,仍可看出金(山)银花之纷争仍未找到科学的解决办法,这可能欠缺对中医临床治病的"异病同治"、"同病异治"与"同证多方"、"一方多证"的用药规律全面分析;更没有深邃分析中药多成分与经络脏腑作用超分子"印迹模板"自主作用规律;也没有关注中药复方多成分的有效性与安全性评价技术的进步;仍然受到了"一药一构一效"唯成分论用药模式影响;再加上中药临床前与临床中的生物等效性研究方法贫匮,终使问题得不到解决。金(山)银花分合列之争表象是地域经济、药物有效性与安全性的生物等效性之争,实际上却是中医药学科临床辨证施治治病的原理之争;更确切地说是中西医治病用药的药物观念之争。该文将梳理金(山)银花研究现状,结合中医临床治病的整体辨证施治与遣药组方治病的"异病同治"、"同病异治"与"同证多方"、"一方多证"的规律;运用超分子"印迹模板"自主作用规律阐明金(山)银花的"异质等效"的中药药理特有规律;并提出金(山)银花生物等效性的研究方法,为解决金(山)花的分合问题,促进中药材产业的发展奠定基础。More and more disputes have happened to confront us continuously since the separation of Japanese（ wild） honeysuckle flower in Chinese Pharmacopoeia in 2005. The state pharmacopeia committee decided to separate Japanese（ wild） honeysuckle flower into two species for japanese（ wild） honeysuckle flower,but didn＇t define their the convincing reasons still did not provide to us as a result that two medicines are not described the differences in natural properties,efficiency and indication,usage and dosage,as well as not given a resolving methodand specific solution. It was known for us that in the history of traditional Chinese medicine（ TCM）,the phenomenenphenomena of the ＂ one drug from multi-species＂ and ＂ one species for multi-drug＂ are very ordinary thingswere ubiquitous.Whether separation of the drug species are separated shall be decided to by clinical efficiency. Through Chinese pharmacopoeia（ 2015edition） issue of Chinese Pharmacopoeia the 2015 issue of the Chinese Pharmacopoeia,we still cannot find a scientific solution for the dispute of for Japanese（ wild） honeysuckle flower,perhaps because of insufficient reorganization of TCM clinical medication regularities,such as ＂ treatment of different diseases with same drug＂, ＂ treatment of the same disease with different drugs＂ and ＂ treatment of the same syndrome with multi-prescriptions＂,and ＂ one prescription treating multiple syndromes＂; lack of in-depth analysis for multicomponent TCM compounds and autonomisation of ＂ supermolecular template＂ for organs and meridians; less attention to the advance of efficacy and safety evaluation technologies for multi-component TCM compounds; impacts from the medication mode of ＂ one ingredientone composition-one effect＂; as well as insufficient research methods for bioequivalent evaluation in preclinic and clinic studies. The dispute for species combination or separation for Japanese（ wild） honeysuckle flower was apparently caused by regional economy,drug biol

关 键 词：金(山)银花 异质等效 超分子化学 印迹模板 中医药基础理论 气析 中药药理学 中医药现代化 经络脏腑 分子拓扑学 分子连接性指数 

分 类 号：R282.71[医药卫生—中药学]